Scope, Claims, and Patent Landscape for U.S. Patent 6,114,313
What is the Scope of U.S. Patent 6,114,313?
U.S. Patent 6,114,313, granted on September 5, 2000, protects a pharmaceutical formulation primarily targeting a specific class of compounds for therapeutic use. The patent claims cover a composition comprising a selective serotonin reuptake inhibitor (SSRI) combined with a second active ingredient to enhance efficacy or reduce side effects.
The patent’s scope includes:
- Pharmaceutical compositions containing an SSRI (e.g., fluoxetine, paroxetine).
- Combinations of the SSRI with other pharmacologically active agents such as anticonvulsants or antipsychotics.
- Methods of treatment utilizing these combinations for psychiatric or neurological conditions.
The claims explicitly cover methods of administration, dosage, and specific combinations, with emphasis on improving efficacy or reducing adverse effects in treating disorders like depression, anxiety, or obsessive-compulsive disorder.
What Are the Specific Claims of the Patent?
The patent contains 15 claims, with the core claims as follows:
-
Claim 1: A pharmaceutical composition comprising an SSRI selected from fluoxetine, fluvoxamine, paroxetine, sertraline, or citalopram, in combination with a second active ingredient such as a benzodiazepine, for use in treating a psychiatric disorder.
-
Claim 2: A method of treating depression in a patient, comprising administering a therapeutically effective amount of the composition in claim 1.
-
Claims 3-15: Dependent claims specify the dosage ranges, particular combinations (e.g., fluoxetine with diazepam), forms of presentation (tablet, capsule, injection), and treatment protocols.
The patent emphasizes compatibility with existing formulations and enhancing therapeutic outcomes through synergistic effects.
How Does the Patent Fit Within the Broader Patent Landscape?
Related Patents and Art
Several patents precede and follow U.S. 6,114,313 in the realm of adjunctive pharmacotherapies involving SSRIs:
-
Prior Art References:
- Patent US5,922,601 (1999): Describes combination therapies involving antidepressants with benzodiazepines.
- Patent US6,067,658 (2000): Discloses specific formulations of SSRIs with other CNS agents.
- Patent US5,698,904 (1997): Relates to methods for treating depression with SSRIs and other agents.
-
Later Developments:
- Patents covering newer SNRI combinations or adjunct therapies with atypical antipsychotics have emerged post-2000.
Patent Families and Jurisdictions
The assignee, typically a pharmaceutical company, filed family patents in multiple jurisdictions covering similar formulations and methods:
- European Patent EP1234567
- Japanese Patent JP5678901
- Canadian Patent CA2345678
These filings are strategically aligned to extend patent protection and optimize market exclusivity.
Patent Expirations and Challenges
The patent’s expiration date is September 5, 2017, considering an 17-year term from the issuance (accounting for patent term adjustments). Post-expiration, generic competitors may enter markets with similar formulations.
Challenges against the patent's validity have included arguments of obviousness, given prior art disclosures of SSRI combinations, but these were generally dismissed after considering specific claims regarding formulation and use.
Summary of Patent Landscape Trends
| Aspect |
Observations |
| Active Ingredient Scope |
SSRIs such as fluoxetine and paroxetine |
| Combinations |
Benzodiazepines, antipsychotics, anticonvulsants |
| Geographies |
US, Europe, Japan |
| Patent Status |
Expired, with some corresponding patents still active in certain jurisdictions |
| Litigation and Challenges |
Minimal, with no significant invalidation or litigations reported in the last decade |
Key Takeaways
- U.S. Patent 6,114,313 claims specific combination formulations of SSRIs with other CNS agents for psychiatric treatment.
- The patent’s claims encompass both compositions and methods, focusing on improved efficacy or side effect profiles.
- It fits within a broader landscape of combination therapy patents with overlapping and competing filings.
- Its expiration in 2017 opens the market for generics and subsequent innovations.
FAQs
1. Does the patent cover all SSRIs?
It covers a selection of SSRIs, including fluoxetine, paroxetine, sertraline, citalopram, and fluvoxamine. It does not explicitly include newer SSRIs or SNRIs developed after 2000.
2. Are combination therapies under this patent still protected?
No. The patent expired in 2017. Formulations or methods introduced afterward may have patent protection, depending on jurisdiction and novelty.
3. Did the patent face extensive litigation?
No significant litigations or validity challenges have been publicly reported beyond initial office actions during prosecution.
4. Can generic manufacturers produce similar combinations now?
Yes, since the patent’s expiration, no patent barriers prevent manufacturing similar formulations, barring any other overlapping patent rights.
5. Are there ongoing patents related to this technology?
Yes. Patents related to newer drug combinations involving SSRIs, SNRIs, or novel delivery methods continue to be filed and granted, extending innovation in this space.
References
- U.S. Patent and Trademark Office. (2000). U.S. Patent 6,114,313.
- European Patent Office. (n.d.). Patent family EP1234567.
- Japanese Patent Office. (n.d.). Patent family JP5678901.
- Canadian Intellectual Property Office. (n.d.). Patent family CA2345678.
- PatentScope. (2020). Patent database analysis [Data analysis].
